Eliaz Therapeutics
Santa Rosa, US · Founded 2015 · California corporation
BiotechHealthtech
Founders & leadership
IE
Isaac EliazExecutive Officer, Director
MG
Milton GossExecutive Officer
Reported raises · per SEC filings
Form D private placements▶$850KraisedOct 2025 · 4 investors · BiotechnologyRule 506(b)
▶$850KraisedOct 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac EliazExecutive Officer, Director
- Milton GossExecutive Officer
- Offering amount
- $850K
- Amount sold
- $850K
- Minimum investment
- $100K
- Proceeds to insiders
- $50K
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedNov 2016 · 1 investors · Other Health CareRule 506(b)
▶$2MraisedNov 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Isaac EliazExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $1M
- First sale
- Nov 2016
- Incorporated
- Corporation, California, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.